Home Pharmaceuticals Cancer Immunotherapy Drug Discovery Outsourcing Market Growth and Profit Analysis, Forecas

Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies and Cancer Vaccines, Others), By Service Type (Target Identification and Validation, Lead Screening and Characterization, Cell-Based Assays), By Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Pancreatic, Head and Neck, Ovarian) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRPH2766DR
Last Updated : Sep 29, 2022
Author : Straits Research
Starting From
USD 2300
Buy Now

Table Of Content

  1. Executive Summary

    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends

    1. Global Cancer Immunotherapy Drug Discovery Outsourcing Market Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Monoclonal Antibodies
        1. By Value
      3. Immunomodulators
        1. By Value
      4. Oncolytic Viral Therapies and Cancer Vaccines
        1. By Value
      5. Others
        1. By Value
    3. By Service Type
      1. Introduction
        1. Service Type By Value
      2. Target Identification and Validation
        1. By Value
      3. Lead Screening and Characterization
        1. By Value
      4. Cell-Based Assays
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung
        1. By Value
      3. Breast
        1. By Value
      4. Colorectal
        1. By Value
      5. Melanoma
        1. By Value
      6. Prostate
        1. By Value
      7. Pancreatic
        1. By Value
      8. Head and Neck
        1. By Value
      9. Ovarian
        1. By Value
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Monoclonal Antibodies
        1. By Value
      3. Immunomodulators
        1. By Value
      4. Oncolytic Viral Therapies and Cancer Vaccines
        1. By Value
      5. Others
        1. By Value
    3. By Service Type
      1. Introduction
        1. Service Type By Value
      2. Target Identification and Validation
        1. By Value
      3. Lead Screening and Characterization
        1. By Value
      4. Cell-Based Assays
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung
        1. By Value
      3. Breast
        1. By Value
      4. Colorectal
        1. By Value
      5. Melanoma
        1. By Value
      6. Prostate
        1. By Value
      7. Pancreatic
        1. By Value
      8. Head and Neck
        1. By Value
      9. Ovarian
        1. By Value
    5. U.S.
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Monoclonal Antibodies
          1. By Value
        3. Immunomodulators
          1. By Value
        4. Oncolytic Viral Therapies and Cancer Vaccines
          1. By Value
        5. Others
          1. By Value
      2. By Service Type
        1. Introduction
          1. Service Type By Value
        2. Target Identification and Validation
          1. By Value
        3. Lead Screening and Characterization
          1. By Value
        4. Cell-Based Assays
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung
          1. By Value
        3. Breast
          1. By Value
        4. Colorectal
          1. By Value
        5. Melanoma
          1. By Value
        6. Prostate
          1. By Value
        7. Pancreatic
          1. By Value
        8. Head and Neck
          1. By Value
        9. Ovarian
          1. By Value
    6. Canada
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Monoclonal Antibodies
        1. By Value
      3. Immunomodulators
        1. By Value
      4. Oncolytic Viral Therapies and Cancer Vaccines
        1. By Value
      5. Others
        1. By Value
    3. By Service Type
      1. Introduction
        1. Service Type By Value
      2. Target Identification and Validation
        1. By Value
      3. Lead Screening and Characterization
        1. By Value
      4. Cell-Based Assays
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung
        1. By Value
      3. Breast
        1. By Value
      4. Colorectal
        1. By Value
      5. Melanoma
        1. By Value
      6. Prostate
        1. By Value
      7. Pancreatic
        1. By Value
      8. Head and Neck
        1. By Value
      9. Ovarian
        1. By Value
    5. U.K.
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Monoclonal Antibodies
          1. By Value
        3. Immunomodulators
          1. By Value
        4. Oncolytic Viral Therapies and Cancer Vaccines
          1. By Value
        5. Others
          1. By Value
      2. By Service Type
        1. Introduction
          1. Service Type By Value
        2. Target Identification and Validation
          1. By Value
        3. Lead Screening and Characterization
          1. By Value
        4. Cell-Based Assays
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung
          1. By Value
        3. Breast
          1. By Value
        4. Colorectal
          1. By Value
        5. Melanoma
          1. By Value
        6. Prostate
          1. By Value
        7. Pancreatic
          1. By Value
        8. Head and Neck
          1. By Value
        9. Ovarian
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Monoclonal Antibodies
        1. By Value
      3. Immunomodulators
        1. By Value
      4. Oncolytic Viral Therapies and Cancer Vaccines
        1. By Value
      5. Others
        1. By Value
    3. By Service Type
      1. Introduction
        1. Service Type By Value
      2. Target Identification and Validation
        1. By Value
      3. Lead Screening and Characterization
        1. By Value
      4. Cell-Based Assays
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung
        1. By Value
      3. Breast
        1. By Value
      4. Colorectal
        1. By Value
      5. Melanoma
        1. By Value
      6. Prostate
        1. By Value
      7. Pancreatic
        1. By Value
      8. Head and Neck
        1. By Value
      9. Ovarian
        1. By Value
    5. China
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Monoclonal Antibodies
          1. By Value
        3. Immunomodulators
          1. By Value
        4. Oncolytic Viral Therapies and Cancer Vaccines
          1. By Value
        5. Others
          1. By Value
      2. By Service Type
        1. Introduction
          1. Service Type By Value
        2. Target Identification and Validation
          1. By Value
        3. Lead Screening and Characterization
          1. By Value
        4. Cell-Based Assays
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung
          1. By Value
        3. Breast
          1. By Value
        4. Colorectal
          1. By Value
        5. Melanoma
          1. By Value
        6. Prostate
          1. By Value
        7. Pancreatic
          1. By Value
        8. Head and Neck
          1. By Value
        9. Ovarian
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Monoclonal Antibodies
        1. By Value
      3. Immunomodulators
        1. By Value
      4. Oncolytic Viral Therapies and Cancer Vaccines
        1. By Value
      5. Others
        1. By Value
    3. By Service Type
      1. Introduction
        1. Service Type By Value
      2. Target Identification and Validation
        1. By Value
      3. Lead Screening and Characterization
        1. By Value
      4. Cell-Based Assays
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung
        1. By Value
      3. Breast
        1. By Value
      4. Colorectal
        1. By Value
      5. Melanoma
        1. By Value
      6. Prostate
        1. By Value
      7. Pancreatic
        1. By Value
      8. Head and Neck
        1. By Value
      9. Ovarian
        1. By Value
    5. UAE
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Monoclonal Antibodies
          1. By Value
        3. Immunomodulators
          1. By Value
        4. Oncolytic Viral Therapies and Cancer Vaccines
          1. By Value
        5. Others
          1. By Value
      2. By Service Type
        1. Introduction
          1. Service Type By Value
        2. Target Identification and Validation
          1. By Value
        3. Lead Screening and Characterization
          1. By Value
        4. Cell-Based Assays
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung
          1. By Value
        3. Breast
          1. By Value
        4. Colorectal
          1. By Value
        5. Melanoma
          1. By Value
        6. Prostate
          1. By Value
        7. Pancreatic
          1. By Value
        8. Head and Neck
          1. By Value
        9. Ovarian
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Monoclonal Antibodies
        1. By Value
      3. Immunomodulators
        1. By Value
      4. Oncolytic Viral Therapies and Cancer Vaccines
        1. By Value
      5. Others
        1. By Value
    3. By Service Type
      1. Introduction
        1. Service Type By Value
      2. Target Identification and Validation
        1. By Value
      3. Lead Screening and Characterization
        1. By Value
      4. Cell-Based Assays
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung
        1. By Value
      3. Breast
        1. By Value
      4. Colorectal
        1. By Value
      5. Melanoma
        1. By Value
      6. Prostate
        1. By Value
      7. Pancreatic
        1. By Value
      8. Head and Neck
        1. By Value
      9. Ovarian
        1. By Value
    5. Brazil
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Monoclonal Antibodies
          1. By Value
        3. Immunomodulators
          1. By Value
        4. Oncolytic Viral Therapies and Cancer Vaccines
          1. By Value
        5. Others
          1. By Value
      2. By Service Type
        1. Introduction
          1. Service Type By Value
        2. Target Identification and Validation
          1. By Value
        3. Lead Screening and Characterization
          1. By Value
        4. Cell-Based Assays
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung
          1. By Value
        3. Breast
          1. By Value
        4. Colorectal
          1. By Value
        5. Melanoma
          1. By Value
        6. Prostate
          1. By Value
        7. Pancreatic
          1. By Value
        8. Head and Neck
          1. By Value
        9. Ovarian
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Cancer Immunotherapy Drug Discovery Outsourcing Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Aquila Biomedical
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Covance, Inc.
    3. Crown Bioscience Inc.
    4. BPS Biosciences Inc.
    5. Horizon Discovery Group PLC
    6. Explicit Immuno-Oncology
    7. Gen script Biotech Corporation
    8. ImmunXperts SA
    9. Promega Corporation
    10. STC Biologics
    11. Molecular Imaging Inc. (MI Bioresearch Inc.)
    12. Celentyx Ltd.
    13. DiscoverX Corporation
    14. HD Biosciences Co. Ltd.
    15. Personalis, Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Drug Discovery Outsourcing Market Size The global drug discovery outsourcing market size was valued at USD 3.29 billion in 2021 and is projected to reach an expected value of USD 6.37 billion by 2030 at a CAGR of 7.6% o
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report


We are featured on :